Matrix metalloproteinases and mesangial remodeling in light chain-related glomerular damage

Kidney International

Volumn 68, Issue 4, 2005, Pages 1590-1603

  Keeling, John ^b   Herrera, Guillermo A ^a  

^a Louisiana State University School of Medicine Shreveport   (United States)

^b NONE

Author keywords

AL amyloidosis (AL Am); Kidney; Light chain deposition disease (LCDD); Matrix metalloproteinases (MMPs); Tissue inhibitors of metalloproteinases (TIMPs)

Indexed keywords

GELATINASE A; GELATINASE B; IMMUNOGLOBULIN LIGHT CHAIN; INTERSTITIAL COLLAGENASE; MATRILYSIN; MESSENGER RNA; STROMELYSIN;

AMYLOIDOSIS; ARTICLE; AUTOPSY; CELL CULTURE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYMOLOGY; EXTRACELLULAR MATRIX; GLOMERULAR DYSFUNCTION; HUMAN; HUMAN CELL; HUMAN TISSUE; KIDNEY BIOPSY; KIDNEY PARENCHYMA; LASER CAPTURE MICRODISSECTION; LIGHT CHAIN DEPOSITION DISEASE; LYSOSOME STORAGE DISEASE; MESANGIUM CELL; MICROARRAY ANALYSIS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; TISSUE DISTRIBUTION; TISSUE REPAIR; ZYMOGRAPHY;

AMYLOIDOSIS; BLOTTING, WESTERN; CELLS, CULTURED; COLLAGEN TYPE IV; CULTURE MEDIA, CONDITIONED; ENZYME-LINKED IMMUNOSORBENT ASSAY; GLOMERULAR MESANGIUM; HUMANS; IMMUNOGLOBULIN LIGHT CHAINS; IMMUNOHISTOCHEMISTRY; MATRIX METALLOPROTEINASE 1; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 3; MATRIX METALLOPROTEINASE 7; MATRIX METALLOPROTEINASE 9; MATRIX METALLOPROTEINASES; RNA, MESSENGER; TENASCIN; TISSUE INHIBITOR OF METALLOPROTEINASES;

EID: 31644449261     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1111/j.1523-1755.2005.00571.x     Document Type: Article

References (57)

1. PARKS WC: Matrix metalloproteinases in repair. Wound Rep Reg 7:423-432, 1999
2. THIENNU H, VU ZW: Matrix metalloproteinases: Effectors of development and normal physiology. Genes Development 14:2123-2133, 2000
3. GAIRE M, MAGBANUA Z, MCDONNELL S, et al: Structure and expression of the human gene for the matrix metalloproteinase matrilysin. J Biol Chem 269:2032-2040, 1994
4. BERNARDO MM, FRIDMAN R: TIMP-2 (tissue inhibitor of metalloproteinases-2) regulates MMP-2 (matrix metalloproteinase-2) activity in the extracellular environment after pro-MMP-2 activation by MT1 (membrane type 1)-MMP. Biochem J 374:739-745, 2003
5. NAGASE H, WOESSNER JF JR.: Matrix metalloproteinases. J Biol Chem 274:21491-21494, 1999
6. EGEBLAD M, WERB Z: New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2:161-174, 2002
7. MURPHY G, STANTON H, COWELL S, et al: Mechanisms for pro matrix metalloproteinase activation. APMIS 107:38-44, 1999
8. BODE W, FERNANDEZ-CATALAN C, TSCHESCHE H, et al: Structural properties of matrix metalloproteinases. Cell Mol Life Sci 55:639-652, 1999
9. HARENDZA S, POLLOCK AS, MERTENS PR, et al: Tissue-specific enhancer-promoter interactions regulate high level constitutive expression of matrix metalloproteinase 2 by glomerular mesangial cells. J Biol Chem 270:18786-18796, 1995
10. TURCK J, POLLOCK AS, LEE LK, et al: Matrix metalloproteinase 2 (gelatinase A) regulates glomerular mesangial cell proliferation and differentiation. J Biol Chem 271:15074-15083, 1996
11. LELONGT B, LELONGT B, PIEDAGNEL R, et al: Do matrix metalloproteinases MMP-2 and MMP-9 (gelatinases) play a role in renal development, physiology and glomerular diseases? Curr Opin Nephrol Hypertens 10:7-12, 2001
12. PARKS W C, MECHAM RP (editors): Matrix Metalloproteinases, San Diego, Academic Press, 1998, pp 1-14
13. MARTIN J, EYNSTONE L, DAVIES M, et al: Induction of metalloproteinases by glomerular mesangial cells stimulated by proteins of the extracellular matrix. J Am Soc Nephrol 12:88-96, 2001
14. KUGLER A: Matrix metalloproteinases and their inhibitors. Anti-cancer Res 19:1589-1592, 1999
15. GOMIS-RUTH FX, MASKOS K, BETZ M, et al: Mechanism of inhibition of the human matrix metalloproteinase stromelysin-1 by TIMP-1. Nature 389:77-81, 1997
16. CHOW CC, Mo KL, CHAN CK, et al: Renal Impairment in patients with multiple myeloma. Hong Kong Med J 9:78-82, 2003
17. HERRERA GA: Renal manifestations of plasma cell dyscrasias: An appraisal from the patient's bedside to the research laboratory. Annals Diagn Pathol 4:174-200, 2000
18. HERRERA GA, RUSSELL WJ, ISAAC J, et al: Glomerulopathic light chain - Mesangial cell interactions modulate in vitro extracellular matrix remodeling and reproduce mesangiopathic findings documented in vivo. Ultrastruct Pathol 23:107-126, 1999
19. TENG J, RUSSELL WJ, GU X, et al: Different types of glomerulopathic light chains interact with mesangial cells using a common receptor but exhibit different intracellular trafficking patterns. Lab Invest 84:440-451, 2004
20. BELLOTTI V, MANGIONE P, MERLINI G: Review: immunoglobulin light chain amyloidosis-the archetype of structural and pathogenic variability. J Struct Biol 130:280-289, 2000
21. ABRAHAM RS, GEYER SM, PRICE-TROSKA TL, et al: Immunoglobulin light chain variable (V) region genes influence clinical presentation and outcome in light chain-associated amyloidosis (AL). Blood 101:3801-3808, 2003
22. SOLOMON A, FRANGIONE B, FRANKLIN EC: λVI subgroup of human light chains with amyloidosis AL. J Clin Invest 70:453-460, 1982
23. L germ line gene use and clonal plasma cell burden. Blood 98:714-720, 2001
24. CHITI F, WEBSTER P, TADDEI N, et al: Designing conditions for in vitro formation of amyloid protofilaments and fibrils. Proc Natl Acad Sci USA 96:3590-3594, 1999
25. COGNE M, SILVAIN C, KHAMLICHI AA, et al: Structurally abnormal immunoglobulins in human immunoproliferative disorders. Blood 79:2181-2195, 1992
26. ABRAHAM RS, GEYER SM, PRICE-TROSKA TL, et al: Immunoglobulin light chain variable (V) region genes influence clinical presentation and outcome in light chain-associated amyloidosis (AL). Blood 101:3801-3808, 2003
27. CHITI F, TADDEI N, BUCCIANTINI M, et al: Mutational analysis of the propensity for amyloid formation by a globular protein. EMBO J 19:1441-1449, 2000
28. CHITI F, TADDEI N, BARONI F, et al: Kinetic partitioning of protein folding and aggregation. Nat Struct Biol 9:137-143, 2002
29. CHITI F, STEFANI M, TADDEI N, et al: Rationalization of the effects of mutations on peptide and protein aggregation rates. Nature 424:805-808, 2003
30. HARPER PA, ROBINSON JM, HOOVER RL, et al: Improved methods for culturing rat glomerular cells. Kidney Int 26:875-880, 1984
31. ISAAC J, KERBY JD, RUSSELL WJ, et al: In vitro modulation of AL-amyloid formation by human mesangial cells exposed to amyloidogenic light chains. Amyloid Int J Exp Clin Invest 5:238-246, 1998
32. ZHU L, HERRERA GA, MURPHY-ULLRICH JE, et al: Pathogenesis of glomerulosclerosis in light chain deposition disease: Role for transforming growth factor-β. Am J Pathol 147:375-385, 1995
33. SHI S, COOTE RJ, TAYLOR CR: Antigen retrieval immunohistochemistry: Past, present, and future. J Histochem Cytochem 45:327-343, 1997
34. STANTON H, GAVRILOVIC J, ATKINSON SJ, et al: The activation of ProMMP-2 (gelatinase A) by HT1080 fibrosarcoma cells is promoted by culture on a fibronectin substrate and is concomitant with an increase in processing of MT1-MMP (MMP-14) to a 45 kDa form. J Cell Sci 111:2789-2798, 1998
35. 1 integrins in monoclonal light chain-related renal diseases. Mod Pathol 10:485-495, 1997
36. SAITO K, SHIMIZU F, SATO T, et al: Modulation of human mesangial cell behaviour by extracellular matrix components - The possible role of interstitial type III collagen. Clin Exp Immunol 91:510-515, 1993
37. KEELING J, TENG J, HERRERA GA: AL-amyloidosis and light-chain deposition disease light chains induce divergent phenotypic transformations of human mesangial cells. Lab Invest 84:1322-1338, 2004
38. SCHNAPER HW, KLEINMAN HK: Regulation of cell function by extracellular matrix. Pediatr Nephrol 7:96-104, 1993
39. LOVETT DH, STERZEL RB, KASHGARIAN M, et al: Neutral proteinase activity produced in vitro by cells of the glomerular mesangium. Kidney Int 23:342-349, 1983
40. DAVIES M, MARTIN J, THOMAS GJ, et al: Proteinases and glomerular matrix turnover. Kidney Int 41:671-678, 1992
41. CHENG S, LOVETT DH: GELATINASE A (MMP-2) is necessary and sufficient for renal tubular cell epithelial-mesenchymal transformation. Am J Pathol 162:1937-1949, 2003
42. WANG M, QIN X, MUDGETT JS, et al: Matrix metalloproteinase deficiencies affect contact hypersensitivity: stromelysin-1 deficiency prevents the response and gelatinase B deficiency prolongs the response. Proc Natl Acad Sci 96:6885-6889, 1999
43. MULLER D, ROESSNER A, ROCKEN C: Distribution pattern of matrix metalloproteinases 1, 2, 3, and 9, tissue inhibitors of matrix metalloproteinases 1 and 2, and alpha 2-macroglobulin in cases of generalized AA- and AL amyloidosis. Virchows Arch 437:521-527, 2000
44. STIX B, KAHNE T, SLETTEN K, et al: Proteolysis of AA amyloid fibril proteins by matrixmetalloproteinases-1, -2, and -3. Am J Pathol 159:561-570, 2001
45. MURRAY GI: Matrix metalloproteinases: a multifunctional group of molecules. J Pathol 195:135-137, 2001
46. NAGASE H, WOESSNER JF JR.: Matrix metalloproteinases. J Biol Chem 274:21491-21494, 1999
47. MIGNATTI P: Extracellular matrix remodeling by metalloproteinases and plasminogen activators. Kidney Int 47:S12-S14, 1995
48. IMAI K, KUSAKABE M, SAKAKURA T, et al: Susceptibility of tenascin to degradation by matrix metalloproteinases and serine proteinases. FEBS Lett 352:216-218, 1994
49. TRUONG LD, PINDUR J, BARRIOS R, et al: Tenascin is an important component of the glomerular extracellular matrix in normal and pathologic conditions. Kidney Int 45:201-210, 1994
50. TRUONG LD, MAJESKY MW, PINDUR J: Tenascin is synthesized and secreted by rat mesangial cells in culture and is present in extracellular matrix in human glomerular diseases. J Am Soc Nephrol 4:1771-1777, 1994
51. KUHN C, MASON RJ: Immunolocalization of SPARC, tenascin, and thrombospondin in pulmonary fibrosis. Am J Pathol 147:1759-1769, 1995
52. SAKAMURA T, KUSANO I: Tenascin in tissue perturbation repair. Acta Pathol Jpn 41:247-258, 1991
53. ERICKSON HP, BOURDON MA: Tenascin: an extracellular matrix protein prominent in specialized embryonic tissues and tumors. Annu Rev Cell Biol 5:71-92, 1989
54. ERICKSON HP: Tenascin-C, tenascin-R and tenascin-X: A family of talented proteins in search of functions. Curr Opin Cell Biol 5:869-876, 1993
55. TSUNODA T, INADA H, KALEMBEYI I, et al: Involvement of large tenascin-C splice variants in breast cancer progression. Am J Pathol 162:1857-1867, 2003
56. KEELING J, DEMPSEY S, JOSEPH L, et al: The role of matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) in mesangial matrix replacement in AL-amyloidosis (AL-Am): An-vivo and in-vitro correlative study, in Amyloid and Amyloidosis, edited by Grateau G, Kyle RA, Skinner M, Boca Raton, CRC Press, 2005, pp 136-138
57. SOLOMON A, WEISS DT: Protein and host factors implicated in the pathogenesis of light chain amyloidosis (AL amyloidosis). Amyloid: Int J Exp Clin Invest 2:269-279, 1995